As part of our series focussing on medicines available in Australia, we have added a product review that outlines the mechanism of action and pharmacology of dupilumab, and the clinical trial evidence (VOYAGE, EXCURSION) that led to regulatory approval of dupilumab for managing uncontrolled moderate-to-severe paediatric asthma with type 2 inflammation.
Guiding commentary has been provided by Dr Geshani Jayasuriya, a Paediatric Respiratory and Sleep Physician at John Hunter Children's Hospital and The Children’s Hospital at Westmead.
Please login below to download this issue (PDF)